Redeye provides an initial comment on BioVica’s Q3 2025/2026 report. Revenues were in line with our estimates, and costs were lower than anticipated. Pharma Services contributed meaningfully in the quarter (as guided by the company in the Q2 report call). Overall, we assess the report as satisfactory, showing that the company is back on track.
LÄS MER
